CSL Pays $102 Million to Acquire Remaining 20% of China's RuiDe Bio

CSL Limited of Australia will pay $102 million to buy the remaining 20% in a China plasma company, Wuhan Zhong Yuan Rui De Biological Products (RuiDe). One year ago, CSL acquired an 80% RuiDe stake from China 's Humanwell Healthcare Group for $352 million. The companies had a previous relationship: CSL had been supplying RuiDe with albumin for China . With the purchase, CSL became a full-fledged participant in China 's plasma collection and products market. More details.... Stock Symbols: (ASX: CSL; USOTC: CSLLY) (SHA: 600079) Share this with colleagues: // //